An overview of the clinical presentation, management approaches, and clinical practice guidelines for immunotherapy-related neurotoxicity in acute lymphoblastic leukemia treatment is presented.

Clinicians should recognize the prognostic importance of minimal residual disease testing and its implications for treatment pathways in acute lymphoblastic leukemia.

Navigating the complexities of acute lymphoblastic leukemia treatment requires a multidisciplinary team approach to the management of multiple care needs in inpatient and outpatient settings.

Successful transitions of care from the hospital to the home setting for patients with acute lymphoblastic leukemia requires a team of hospital and outpatient clinicians to provide coordinated care and support.

In a follow-up analysis, second-line nivolumab in advanced/recurrent esophageal squamous-cell carcinoma showed significant median overall survival benefit compared with chemotherapy.

Promising antitumor activity and a tolerable safety profile were found in patients with previously treated gastric or gastroesophageal cancer treated with trifluridine/tipiracil combined with ramucirumab.

Insertion-deletion rate and high tumor mutation burden in advanced gastric cancer was found to be associated with favorable progression-free survival and overall survival in patients treated with nivolumab.

Treatment with surufatinib in combination with toripalimab is associated with promising responses and manageable adverse events in previously treated gastric or gastroesophageal junction adenocarcinoma.

Post-hoc analysis of the CheckMate-032 study found PD-L1 expression by combined positive score was more closely associated with nivolumab and ipilimumab therapy efficacy compared with percentage of positive tumor cells PD-L1 expression in advanced gastric/gastroesophageal junction cancer.